Cellular and Molecular Life Sciences CMLS

, Volume 59, Issue 12, pp 2184–2190

Susceptibility of recombinant porcine endogenous retrovirus reverse transcriptase to nucleoside and non-nucleoside inhibitors

  • M. Wilhelm
  • J. A. Fishman
  • R. Pontikis
  • A.-M. Aubertin
  • F. X. Wilhelm
Research Article

DOI: 10.1007/s000180200017

Cite this article as:
Wilhelm, M., Fishman, J., Pontikis, R. et al. CMLS, Cell. Mol. Life Sci. (2002) 59: 2184. doi:10.1007/s000180200017

Abstract.

Transplantation of organs, tissues or cells from pigs to humans could be a potential solution to the shortage of human organs for transplantation. Porcine endogenous retroviruses (PERVs) remain a major safety concern for porcine xenotransplantation. Thus, finding drugs that could be used as virological prophylaxis (or therapy) against PERV replication would be desirable. One of the most effective ways to block retroviral multiplication is to inhibit the enzyme reverse transcriptase (RT) which catalyzes the reverse transcription of viral RNA to proviral double-stranded DNA. We report here the cloning and expression of PERV RT and its susceptibility to several inhibitors. Our data demonstrate PERV susceptibility in vitro to the triphosphorylated nucleoside analog of zidovudine (AZT) and to ddGTP and to a lesser extent to ddTTP but almost no susceptibility to the non-nucleoside RT inhibitors tested.

Key words. Porcine endogenous retrovirus; reverse transcriptase; inhibitors.

Copyright information

© Birkhäuser Verlag, 2002

Authors and Affiliations

  • M. Wilhelm
    • 1
  • J. A. Fishman
    • 2
  • R. Pontikis
    • 3
  • A.-M. Aubertin
    • 4
  • F. X. Wilhelm
    • 1
  1. 1.Institut de Biologie Moléculaire et Cellulaire, 15, rue René Descartes, 67084 Strasbourg (France), Fax +33388602218, e-mail: wilhelm@ibmc.u-strasbg.fr FR
  2. 2.Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (USA) US
  3. 3.Institut Curie, UMR CNRS 176, Paris (France)FR
  4. 4.Institut de Virologie, U 74 INSERM, Strasbourg (France) FR